Movfor Capsule (Molnupiravir 200 mg) | Lagevrio Alternative | Treats Mild to Moderate COVID-19 in High-Risk Adults
Movfor Capsule (Molnupiravir 200mg) is an oral antiviral capsule used to treat mild to moderate COVID-19 in high-risk adults. Reduces viral load and lowers the risk of hospitalisation and death. To be started within 5 days of symptom onset.
Product Overview
Movfor Capsule is an orally administered antiviral medication containing Molnupiravir (200 mg). Developed as a targeted therapy for viral respiratory infections, it specifically acts as a nucleoside analogue that interferes with the replication process of certain RNA viruses. It is primarily utilized to treat mild-to-moderate viral illnesses in adults who are at a higher risk of progressing to severe disease, helping to reduce the viral load and accelerate recovery.
Product Composition
- Active Ingredient: Molnupiravir
- Strength: 200 mg per capsule
- Pharmacological Class: Nucleoside Analogue / Antiviral
- Formulation: Hard gelatin capsule for oral administration
- Excipients: May include microcrystalline cellulose, hydroxypropyl cellulose, and magnesium stearate
Product Specifications
| Feature | Specification |
| Drug Category | Antiviral Agent |
| Therapeutic Class | RNA Polymerase Inhibitor |
| Route of Administration | Oral (Systemic) |
| Standard Treatment Course | Typically 5 days |
| Bioavailability | Rapidly absorbed after oral administration |
Mechanism of Action
- Viral Mutagenesis: Molnupiravir is a prodrug that is metabolized into the ribonucleoside analogue N4-hydroxycytidine (NHC). Once inside the virus-infected cells, it is incorporated into the viral RNA by the enzyme RNA-dependent RNA polymerase.
- Error Catastrophe: The medication works by inducing "lethal mutagenesis." It introduces widespread errors into the genetic code of the virus during replication.
- Inhibition of Replication: As these genetic errors accumulate, the virus becomes unable to produce functional proteins or replicate its genome correctly. This effectively halts the spread of the virus within the host’s body.
- Viral Load Reduction: By preventing the production of new, viable viral particles, Movfor helps the body's immune system clear the existing infection more efficiently.
Key Benefits
- Convenient Oral Therapy: Unlike many antiviral treatments that require intravenous (IV) infusion in a hospital setting, Movfor can be taken easily at home.
- Early Intervention: Designed to be administered shortly after the onset of symptoms, preventing the infection from reaching a critical or life-threatening stage.
- Broad-Spectrum RNA Activity: The mechanism of inducing genetic errors is effective across various strains and mutations of RNA viruses.
- Reduced Hospitalization Risk: Clinical data suggests that early treatment significantly lowers the likelihood of disease progression and the need for intensive medical care.
- Fast-Acting Formula: Reaches peak plasma concentrations quickly, allowing the antiviral action to begin shortly after the first dose.
Precautions
Medical supervision
- Use Movfor Capsule (Molnupiravir 200 mg) only under medical supervision
- Start treatment as early as possible after diagnosis
- Do not skip doses or stop treatment early
- Complete the full prescribed course
Pregnancy and breastfeeding
- Not recommended during pregnancy unless specifically advised
- Effective contraception should be used during treatment
- Breastfeeding should be avoided during and shortly after treatment (as advised)
Reproductive safety
- May pose risk to fetal development based on animal studies
- Men and women of reproductive age should use reliable contraception
- Continue contraception for a period after treatment as advised by a doctor
Health conditions
| Condition | Precaution |
|---|---|
| Severe COVID-19 | Not intended for hospitalized or severe cases |
| Liver disease | Use with caution and monitoring |
| Kidney disease | Usually no adjustment needed, but doctor should evaluate |
| Weak immunity | Requires close monitoring |
General safety
- Not a substitute for COVID-19 vaccination
- Do not use for prevention unless prescribed
- Do not share medication with others
Monitoring advice
- Watch for worsening symptoms like breathlessness or chest pain
- Seek immediate medical attention if condition worsens
- Follow isolation and infection control guidelines during treatment
Lifestyle precautions
- Stay hydrated and take adequate rest
- Avoid alcohol if feeling weak or unwell
- Follow all instructions from your healthcare provider strictly
Usage
Movfor Capsule must be taken exactly as prescribed by a healthcare provider. To achieve the best clinical outcome, it is essential to begin the treatment as soon as possible after a diagnosis is confirmed and within the first few days of symptom onset.
Dosage and Administration
Adhering to the full treatment course is vital to ensure the virus is effectively neutralized and to prevent the potential for viral resistance.
Treatment Duration: The medication is taken for a total of 5 consecutive days. Even if you begin to feel better before the course is finished, you must complete all doses.
Administration Method: Capsules should be swallowed whole with a glass of water. They can be taken with or without food.
Timing: Try to take your doses at the same time every morning and evening to maintain a consistent level of the antiviral in your system.
Crushing/Opening: Do not open, break, or chew the capsules; they should be swallowed intact to ensure the correct release of the medication.
Contraception and Pregnancy: Due to the mechanism of the drug, effective contraception is required during treatment and for a specified period after the final dose (4 days for females; 3 months for males). This medication is generally not recommended during pregnancy.
Breastfeeding: It is advised to avoid breastfeeding during the 5-day treatment period and for 4 days after the last dose.
Missed Dose: If you miss a dose and it has been less than 10 hours, take it immediately. If more than 10 hours have passed, skip the missed dose and return to your regular schedule. Do not take a double dose.
Uses
Movfor Capsule is indicated for the treatment of specific viral infections in adults to prevent the progression of the illness.
Primary Therapeutic Uses
Treatment of Mild-to-Moderate Viral Infections: Specifically used for laboratory-confirmed cases of certain RNA viral infections (such as SARS-CoV-2) in adults.
Management of High-Risk Patients: Indicated for individuals who have at least one risk factor for developing severe illness, such as obesity, older age, diabetes, or heart disease.
Reduction of Viral Shedding: Helps decrease the amount of virus present in the respiratory tract, which may assist in clearing the infection more rapidly.
Prevention of Hospitalization: The primary goal of therapy is to reduce the risk of the infection progressing to a stage that requires supplemental oxygen or hospital admission.
Emergency Use in Outpatient Settings: Provided as a critical oral option for managing outbreaks where early intervention is necessary to protect vulnerable populations.
FAQs
Q: What is Movfor Capsule used for?
A: Movfor Capsule is used to treat mild to moderate COVID-19 in adults who have a high risk of disease progression, including hospitalisation or death. It is used in patients with an oxygen saturation (SpO2) greater than 93% who are not hospitalised at the time of treatment initiation.
Q: How does Movfor Capsule work?
A: Molnupiravir is a prodrug that is converted in the body to an active antiviral compound. It works by incorporating itself into the RNA of the COVID-19 virus, causing an accumulation of errors in the viral genome known as viral error catastrophe.
Q: When should Movfor Capsule be started?
A: Movfor Capsule should be started within 5 days of the onset of COVID-19 symptoms. It is most effective when initiated early in the course of the illness.
Q: What are the common side effects of Movfor Capsule?
A: Common side effects include nausea, vomiting, diarrhoea, dizziness, and headache. Most are mild and resolve on their own. Consult your doctor if they persist or worsen.
Q: Who should not take Movfor Capsule?
A: Movfor Capsule should not be taken by patients who are allergic to Molnupiravir, children and adolescents below 18 years of age, pregnant women, or patients requiring immediate hospitalisation due to severe COVID-19. It should not be used for more than 5 consecutive days or for prevention of COVID-19.
Q: Can Movfor Capsule be used during pregnancy?
A: No, Movfor Capsule is contraindicated during pregnancy as Molnupiravir may cause harm to the developing baby. Women of childbearing potential should use reliable contraception during treatment and for 4 days after the last dose.
Q: Is Movfor Capsule safe during breastfeeding?
A: Movfor Capsule is not recommended during breastfeeding. Consult your doctor before taking this medicine while breastfeeding.
Q: Can Movfor Capsule be used in children?
A: No, Movfor Capsule is not recommended for children and adolescents below 18 years of age. It is only authorised for use in adults.
Q: Can Movfor Capsule be used in patients with severe COVID-19?
A: No, Movfor Capsule is not indicated for patients with severe COVID-19 requiring hospitalisation. Clinical trials have shown that patients hospitalised with severe COVID-19 have not benefited from Molnupiravir treatment.
Interactions
Other antiviral medicines
- Avoid combining with other COVID-19 antivirals unless prescribed
- May increase risk of side effects or overlapping effects
- Use only under specialist supervision
Immunosuppressive medicines
- Patients on immune-suppressing drugs require close monitoring
- Infection response and recovery may differ
- Dose or treatment plan may need adjustment
Hormonal medicines
- No well-established significant interactions reported
- Still, use contraception as advised during treatment
- Inform doctor about all ongoing hormonal therapy
Antibiotics and supportive medicines
- Generally safe when used together if prescribed
- No major known direct interactions
- Monitoring is still recommended in complex cases
Other medicines and supplements
- Limited interaction data available
- Always inform healthcare provider about all prescription, OTC, and herbal products
- Avoid self-medication during COVID-19 treatment
General advice
- Take Movfor exactly as prescribed
- Do not start or stop any medicines without medical guidance
- Follow strict medical supervision during the entire treatment course
| Manufacturer | : | Hetero Healthcare Limited |
| Trade Name | : | Lagevrio |
| Generic Search | : | Molnupiravir |
| Strength | : | 200mg |
Latest Products
